|
Q2 FY2026
As of Jun 30, 2026
|
Q1 FY2026
As of Mar 31, 2026
|
Q4 FY2025
As of Dec 31, 2025
|
Q3 FY2025
As of Sep 30, 2025
|
Q2 FY2025
As of Jun 30, 2025
|
Q1 FY2025
As of Mar 31, 2025
|
Q4 FY2024
As of Dec 31, 2024
|
Q3 FY2024
As of Sep 30, 2024
|
Q2 FY2024
As of Jun 30, 2024
|
Q1 FY2024
As of Mar 31, 2024
|
Q4 FY2023
As of Dec 31, 2023
|
Q3 FY2023
As of Sep 30, 2023
|
Q2 FY2023
As of Jun 30, 2023
|
Q1 FY2023
As of Mar 31, 2023
|
Q4 FY2022
As of Dec 31, 2022
|
Q3 FY2022
As of Sep 30, 2022
|
Q2 FY2022
As of Jun 30, 2022
|
Q1 FY2022
As of Mar 31, 2022
|
Q4 FY2021
As of Dec 31, 2021
|
Q3 FY2021
As of Sep 30, 2021
|
|
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ASSETS | ||||||||||||||||||||
| Cash and due from banks | ||||||||||||||||||||
| Restricted cash | ||||||||||||||||||||
| Federal funds sold | ||||||||||||||||||||
| Securities available for sale, at fair value | ||||||||||||||||||||
| Restricted equity investments | ||||||||||||||||||||
| Other equity investments | ||||||||||||||||||||
| Other investments | ||||||||||||||||||||
| Loans held for sale | ||||||||||||||||||||
| Paycheck Protection Program loans, net of deferred fees and costs | ||||||||||||||||||||
| Loans held for investment, net of deferred fees and costs | ||||||||||||||||||||
| Less: allowance for credit losses | ||||||||||||||||||||
| Loans held for investment, net | ||||||||||||||||||||
| Accrued interest receivable | ||||||||||||||||||||
| Other real estate owned ("OREO") | ||||||||||||||||||||
| Premises and equipment, net | ||||||||||||||||||||
| Right-of-use assets | ||||||||||||||||||||
| Bank owned life insurance | ||||||||||||||||||||
| Goodwill | ||||||||||||||||||||
| Other intangible assets | ||||||||||||||||||||
| Mortgage derivative asset | ||||||||||||||||||||
| Mortgage servicing rights | ||||||||||||||||||||
| Deferred tax asset, net | ||||||||||||||||||||
| Other assets | ||||||||||||||||||||
| Total assets | ||||||||||||||||||||
| LIABILITIES & STOCKHOLDERS' EQUITY | ||||||||||||||||||||
| Deposits: | ||||||||||||||||||||
| Noninterest-bearing demand | ||||||||||||||||||||
| Interest-bearing demand and money market | ||||||||||||||||||||
| Savings | ||||||||||||||||||||
| Time | ||||||||||||||||||||
| Total deposits | ||||||||||||||||||||
| FHLB borrowings | ||||||||||||||||||||
| FRB borrowings | ||||||||||||||||||||
| Subordinated notes, net | ||||||||||||||||||||
| Lease liabilities | ||||||||||||||||||||
| Dividends payable | ||||||||||||||||||||
| Other liabilities | ||||||||||||||||||||
| Total liabilities | ||||||||||||||||||||
| Stockholders’ Equity: | ||||||||||||||||||||
| Common stock, no par value; 150,000,000 shares authorized at June 30, 2026 and December 31, 2025, respectively; and 89,655,211 and 91,475,278 shares issued and outstanding at June 30, 2026 and December 31, 2025, respectively | ||||||||||||||||||||
| Preferred stock, $50 per share par value; 250,000 shares authorized at September 30, 2024 and December 31, 2023; 2,732 Series C shares and 0 shares issued and outstanding at September 30, 2024 and December 31, 2023, respectively | ||||||||||||||||||||
| Additional paid-in capital | ||||||||||||||||||||
| Accumulated deficit | ||||||||||||||||||||
| Accumulated other comprehensive loss, net of tax | ||||||||||||||||||||
| Total stockholders’ equity | ||||||||||||||||||||
| Total liabilities and stockholders’ equity | ||||||||||||||||||||
Loading...
